TAS-102 is a new oral anti-
tumor drug preparation, composed of a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-tri-fluorothymidine (FTD) and
thymidine phosphorylase inhibitor (TPI).
TAS-102 is currently undergoing clinical trials, and has been demonstrated to have at least 2 mechanisms; inhibition of
thymidylate synthase (TS) and incorporation into
DNA.
5-FU is widely used in the treatment of solid
tumor, but the inherent or acquired resistance of certain
tumors to
5-FU therapy is a major clinical problem. In the present study, we investigated FTD in vitro and in vivo comparing with
5-FU and using FU-resistant cells. There was no relationship between FTD and
5-FU growth inhibition effect in vitro. A different sensitivity pattern was observed by the log-mean graph. We next investigated the anti-
tumor activity of
TAS-102 in a FU-resistant xenograft model. Comparative efficacy was observed between FU-resistant cell and its parent cell. We also studied the influence of
TAS-102 on liver
metastasis in a mouse model of human
colorectal cancer, because liver
metastasis of
colorectal cancer is associated with patient survival. Human
cancer DNA was detected by PCR, and
TAS-102 markedly inhibited the number of liver
metastasis. A novel
angiogenic factor,
platelet-derived endothelial cell growth factor (
PD-ECGF), was shown to be identical to a previously characterized intracellular
enzyme,
thymidine phosphorylase,
TAS-102 can be expected to have not only anti-
tumor cytocidal effects but also antiangiogenesis activity and may inhibit liver
metastasis. Our findings suggested that
TAS-102 is a promising candidate for clinical use and can be expected to decrease
minimal residual disease.